"Mr. Chen, the United Kingdom, Serbia, Ukraine, Russia, Japan and South Korea have successively passed the listing approval of our genetic agents. The sales department has also selected dealers in these countries. They are all top pharmaceutical companies in various countries. They have had long-term cooperative relations with multinational medical groups such as Medtronic and GE Medical."

"In addition, our company's offices in various countries have also been opened one after another. At present, branches have been established in more than 20 countries and regions, offices have been established in more than 50 countries. The branch employees are not less than 50, and the office employees are not less than 20."

"These staff scattered in countries around the world can fully support Ruikang's sales and service and promotion work in more than 70 countries mentioned above!"

"Well, it's done well." Chen Changan nodded with satisfaction and praised Guan Kou.

Regarding the company's expansion, when Ruikang's artificial hematopoietic equipment successfully entered other countries, the company was doing this.

Every time artificial hematopoietic equipment is sold to a country, an office will be established locally. If it is a country with relatively developed economy and a large population, branches will be established.

On the one hand, this is for the subsequent maintenance of artificial hematopoietic equipment and the production of hematopoietic stem cells, and on the other hand, it is also to expand Ruikang's sales channels and connections abroad.

After genetic agents began to be marketed in various countries one after another, Ruikang's foreign offices and branches have established more.

Up to now, more than 20 branches and more than 50 offices have been established, greatly opening up Ruikang's sales channels.

Branches and offices established in various countries generally take into account after-sales issues and are responsible for consultations on cooperation with local agency sales companies. Sometimes promotion work is also needed.

After all, the earth is so big that if Ruikang wants to sell its products to all parts of the world, it must establish sales channels in all countries. It can be imperfect, but it must be there.

With this delay in taking genetic medicine, Ruikang Medical's global expansion has accelerated a lot.

Now even Africa has several Ruikang Medical offices, with not many employees, and each office has only about ten people.

However, these ten people can maintain Ruikang Medical's local sales and promotion work, cooperate with suitable agents, and coordinate with the head office at any time, report on the situation regularly, and sell Ruikang's products locally, and actually grasp the local sales situation and regulate them at any time.

However, Chen Changan was very ambitious and was far from satisfied.

"I don't know when Ruikang can set up offices and branches in 233 countries and regions around the world. This is the courage that a global medical group should have."

For example, GE Medical, or top multinational medical groups such as Siemens, Medtronic, and Philips, their tentacles are spread all over the world. As long as there are places where humans live, there will definitely be employees of their company and their company offices.

Several major medical groups have hundreds of thousands of employees, almost all over the world.

This is also the difference between medical companies and ordinary companies. A vital medical group can definitely affect the entire world and will not be ignored by any individual or organization. After all, medical services will be needed if there are people.

If medical services are needed, their company's products must be used.

This is far from Ruikang's reach. Although these five or six products under Ruikang are all very good and advanced, the quantity is still too small. There is still a big gap between the awesome ability of medical giants to support the supply of all medical equipment in the entire country by hundreds of products.

Chen Changan once said in private that even if other companies in this world go bankrupt, these giants that make medical products will not go bankrupt.

Even if the oil giants collapse, they may still exist.

After all, a person’s life cannot escape birth, old age, sickness and death, and these four words are all related to medical care.

Chen Changan sighed that the road ahead was difficult and he still needed to work hard. He turned to Guan Kou and asked: "What is the current situation in Europe and the United States? Is it still tough to drag our product approval work and not pass it?"

Guan Kou helped his forehead and sighed: "After Japan and South Korea turned against each other, some Eastern European countries were intentional and wanted to introduce our cardiomyocyte healing agents. However, because the company is really unable to handle the import and export affairs of dozens of countries at once, we can only slow down for the time being."

"Now just by negotiating cooperation with agents and dealers in the Middle East and Southeast Asian countries, all employees in the company are already busy, especially Manager Yu Cheng, who, as the head of the company's financial department, works overtime every day and doesn't close his eyes for three days."

"The introduction and cooperation between South Africa and other African countries has been almost done. The first batch of genetic drugs exported have been shipped at Tianjin Customs. However, because it takes two months for sea transportation, our genetic drugs are only valid for one year. The first batch will only transport one million pieces first, and will be supplied every three months in the future."

"And Tiantan Biology is also working overtime every day to produce, and all the remaining production capacity has been invested in the OEM of our company's genetic medicine."

"Mr. Li was very excited when he first received an order of 2 million. After we added another order of 5 million, Mr. Li's attitude changed. He told me more than once that he hoped we could slow down a little, and the production capacity was really limited."

Although Tiantan Biological has the ability to produce tens of millions of vaccines per month, that is the maximum production capacity, and vaccine production is much simpler than the production of genetic drugs.

While they are producing for Ruikang, they also need to give priority to ensuring their vaccine production capacity. If the production capacity that can be evenly produced is enough, they will only produce one million units per month.

Guan Kou said with a subtle expression: "Mr. Chen, in fact, it may not be a good thing for European and American countries to prevent our products from being launched. The company is already a little overwhelmed with export and sales matters in more than 20 countries. The production capacity of OEM factories is not enough and it is impossible to supply the demand of more countries."

"Even if European and American countries have passed our listing approval, we are likely to be unable to provide genetic medicines to these countries. At that time, we may have to bear the anger of the people of various countries."

"It's actually quite good to maintain the current state. It only takes about half a year. The sales situation in the Middle East and Southeast Asian countries should be stable, and the cooperation between agents can be negotiated. It's not too late for us to enter the European and American markets again."

"Now we really have the will but not the strength."

Selling genetic medicine is different from selling artificial hematopoietic equipment. Gene medicine is sold to hospitals and the public, and it often costs orders of millions or even tens of millions of units.

The sale of artificial hematopoietic equipment is sold to the medical systems of various countries, and it is also a large production equipment. It is enough to buy dozens or hundreds of units in a country. It does not require contact with ordinary consumers. Just sell it directly to the government. Ruikang only needs to be responsible for production, which is quite easy to handle.

However, selling genetic drugs requires building a very large sales channel. Ruikang needs to find one or more agency companies in various countries, and then these agency companies will be distributed to agents at all levels, and the agents will be sold to hospitals.

Although Ruikang only needs to connect with agency companies from various countries, the work in this area alone is very huge, and it also requires management from top to bottom, setting up new branches and offices, dispatching employees, and then doing a good job in product OEM, transportation, import and export approval and other links, which is very troublesome.

The most important thing is that the production capacity is insufficient. How could Ruikang be able to supply so many countries around the world at once? It is probably difficult to come with three OEMs at the same level as Tiantan Biology!

So Ruikang actually needs a buffer period, selling bit by bit, first dealing with Southeast Asia and the Middle East markets, then dealing with Asian and African markets, and finally considering European and American markets.

Now North America and Europe are dragging Ruikang's listing approval, but it is not only not a bad thing for Ruikang, but also a good thing.

On the one hand, it can increase Ruikang's reputation. Now, Ruikang Medical's genetic agent has made a big splash with the demonstrations in various countries. Everyone knows that there is such an awesome company in China with such powerful medical technology.

On the one hand, the pressure has also been diverted. If countries do not stop the launch of Ruikang products at all and even welcome them, Ruikang will actually be embarrassed. Its production capacity is insufficient and cannot be supplied to countries around the world for a while. In this case, any country that Ruikang gives priority to supply will offend other countries.

Why can they use genetic medicine first, but we are out of stock and cannot use it?

This will be blocked. On the contrary, Ruikang can express its integrity and openly that due to different government policies in various countries, we are temporarily unable to list in some countries. We are very sorry for this and will continue to actively promote approval work, hoping to obtain listing approval in some countries as soon as possible!

Wouldn't the blame be thrown out like this?

This is a naked plot.

If you pass the approval, my products can be sold unimpededly in Europe and the United States. Even if the production capacity is insufficient for a while, as long as Ruikang finds a few more OEM factories, it will be able to produce a large number of genetic agents in a few months to hit the pacemaker market in various countries.

If you fail to pass the approval, it can also alleviate the problem of insufficient capacity supply for Ruikang and bear the public's surging public pressure for Ruikang Medical.

No matter how you calculate Chen Changan, you will make money.
Chapter completed!